Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. (2022)

First Author: Jenkin D

Attributed to: UoOxford Confidence in Concept 2013 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2666-5247(22)00126-4

PubMed Identifier: 35907430

Publication URI: http://europepmc.org/abstract/MED/35907430

Type: Journal Article/Review

Volume: 3

Parent Publication: The Lancet. Microbe

Issue: 9

ISSN: 2666-5247